Of these the PD-L1 and MABs are the most advanced, a number with FDA approvals and used as standard of care for a few cancers. Side effects can be nasty but oft

Of these the PD-L1 and MABs are the most advanced, a number with FDA approvals and used as standard of care for a few cancers. Side effects can be nasty but often controlled by backing off the treatment or steroids (most problems are the immune system attacking the wrong thing like thyroid, colon, pancreas, etc). They’ve been game changing with nearing 50% success rates for some cancers - hence the Nobel prizes. But that still leaves 50% or more. mRNA as a platform is really exciting, but most current trials are personalised and very labour intensive, so intake/trial sites are minimal.